Literature DB >> 2780006

Malignant transformation of spontaneously regressed retinoblastoma, retinoma/retinocytoma variant.

R C Eagle1, J A Shields, L Donoso, R S Milner.   

Abstract

The authors report on a case of a 7-year-old girl who was found on routine preschool screening at age 4 years to have unilateral decreased vision and a retinal lesion consistent clinically with the retinoma or retinocytoma variant of "spontaneously regressed retinoblastoma." The patient was followed closely with photographic documentation. After remaining stable for 3 years, her tumor grew rapidly and seeded the vitreous, prompting enucleation. Histopathologic examination disclosed that the newer elevated part of the tumor was an undifferentiated retinoblastoma, whereas the base of the tumor had the characteristic benign histopathologic features of retinoma/retinocytoma including bland nuclei, a fibrillar eosinophilic stroma, scattered fleurettes, calcific foci within viable tumor, and no mitoses. Immunohistochemical stains disclosed that immunoreactivity for retinal S antigen, S-100 protein, and glial fibrillary acidic protein was confined to cells in the differentiated basal part of the tumor. These histopathologic observations support the concept that tumors with the clinical characteristics of the patient's original lesion are benign variants of retinoblastoma that have arisen de novo rather than retinoblastomas that have undergone spontaneous regression. The clinical developments in this case suggest that retinomas or retinocytomas rarely undergo malignant transformation after a period of clinical dormancy and underscore the necessity for close follow-up of patients with presumed regressed retinoblastoma.

Entities:  

Mesh:

Year:  1989        PMID: 2780006     DOI: 10.1016/s0161-6420(89)32714-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

1.  Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway.

Authors:  Huixue Wang; Jie Yang; Hui Pan; Mei Chee Tai; Mohamed H Maher; Renbing Jia; Shengfang Ge; Linna Lu
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147

Review 2.  Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future.

Authors:  Ling Wang; Shixu Li; Jun Mei; Lin Ye
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

3.  Germline mutations in retinoma patients: relevance to low-penetrance and low-expressivity molecular basis.

Authors:  Hana Abouzeid; Daniel F Schorderet; Aubin Balmer; Francis L Munier
Journal:  Mol Vis       Date:  2009-04-17       Impact factor: 2.367

4.  A new rosette in retinoblastoma.

Authors:  Dipankar Das; Kasturi Bhattacharjee; Sumita Sarma Barthakur; Prerana Sushil Tahiliani; Panna Deka; Harsha Bhattacharjee; Apurba Deka; Rajashree Paul
Journal:  Indian J Ophthalmol       Date:  2014-05       Impact factor: 1.848

Review 5.  Genetic perspective of retinoblastoma: From present to future.

Authors:  Madhavan Jagadeesan; Vikas Khetan; Ashwin Mallipatna
Journal:  Indian J Ophthalmol       Date:  2016-05       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.